Abstract
Purpose: To determine the efficacy of Lycium barbarum polysaccharide (LBP) in ovarian cancer, and the synergistic effect when used in combination with paclitaxel/cisplatin (PXT∕DDP). Methods: ID-8 cells were injected subcutaneously into 5 groups of female C57BL/6 mice (5 mice/group): control (Con), chemotherapy (CH, PTX/DDP), combination therapy 1 (co-CH1, PTX/DDP + 50 mg/kg LBP), combination therapy 2 (co-CH2, 100 mg/kg LBP) and combination therapy 3 (co-CH3, 150 mg/kg LBP). Tissue morphological changes were monitored by hematoxylin and eosin (H&E) staining. Protein and mRNA levels of Keap1, Nrf2) and heme oxygenase-1 (HemO-1) were analyzed by western blotting and real-time polymerase chain reaction (PCR), as applicable. Results: Growth rate and volume of tumors were significantly reduced in the chemotherapy and combination therapy groups, while organ index increased significantly in co-CH group. Morphological structure of tumor, liver and kidney became normal after combination therapy. Levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), uric acid (UA), creatinine (Cr) and blood urea nitrogen (BUN) were significantly decreased in co-CH group relative to CH group. Lymphocytes, monocytes (MNC), neutrophils, basophils and eosnophils were significantly regulated by combination therapy. In CH and co-CH1-3 groups, the mRNA and protein levels of Keap1, HO-1 and Nrf2 were significantly increased relative to those of control mice. Conclusion: LBP in combination with PXT∕DDP enhances the efficacy of the latter, and reduced its toxicity when used for the treatment of ovarian malignant tumor in mice, by activating Keap1/Nrf2 pathway and promoting immunity. Keywords: Lycium barbarum polysaccharide (LBP), Paclitaxel/Cisplatin, Keap1/Nrf2 pathway, Cytotoxicity
Highlights
It is generally known that ovarian cancer is a serious health and life threat to women
The efficacy of Lycium barbarum polysaccharide (LBP) in ovarian cancer, and its synergistic effects when used in combination with paclitaxel/cisplatin (PXT∕DDP) were investigated
Venous blood was subjected to complete blood count (CBC), which was performed with an automated analyzer MS4 (Melet Schloesing 4, Germany) used for in vitro diagnostic tests
Summary
It is generally known that ovarian cancer is a serious health and life threat to women. The efficacy of LBP in ovarian cancer, and its synergistic effects when used in combination with paclitaxel/cisplatin (PXT∕DDP) were investigated. The combination of PXT and DDP has been in use as the first-line drugs for ovarian cancer. The combination kills both malignant cells and normal cells, leading to poor prognosis and poor quality of life for the patient [6, 7].Obtained from the bark of yew roots, paclitaxel is a unique medicinal extract authorized for use in the control of the growth of cancer cells [7]. P < 0.05 was taken as indicative of significant difference
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
